Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:ATCCode |
J05AX27
|
| gptkbp:CASNumber |
2349386-89-4
|
| gptkbp:chemicalFormula |
C13H19N3O7
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics |
| gptkbp:genericName |
gptkb:molnupiravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lagevrio
|
| gptkbp:indication |
gptkb:COVID-19
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
RNA polymerase inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea dizziness headache |
| gptkbp:bfsParent |
gptkb:MRK
|
| gptkbp:bfsLayer |
5
|